國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Approaching complex diseasesnetwork-...

Bizzarri, Mariano.

Approaching complex diseasesnetwork-based pharmacology and systems approach in bio-medicine /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Approaching complex diseasesedited by Mariano Bizzarri.
其他題名:	network-based pharmacology and systems approach in bio-medicine /
其他作者:	Bizzarri, Mariano.
出版者:	Cham :Springer International Publishing :2020.
面頁冊數:	xvi, 483 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Drug development.
電子資源:	https://doi.org/10.1007/978-3-030-32857-3
ISBN:	9783030328573$q(electronic bk.)

Approaching complex diseasesnetwork-based pharmacology and systems approach in bio-medicine /
Approaching complex diseasesnetwork-based pharmacology and systems approach in bio-medicine /[electronic resource] :edited by Mariano Bizzarri. - Cham :Springer International Publishing :2020. - xvi, 483 p. :ill., digital ;24 cm. - Human perspectives in health sciences and technology,v.22661-8915 ;. - Human perspectives in health sciences and technology ;v.2..

This volume - for pharmacologists, systems biologists, philosophers and historians of medicine - points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.

ISBN: 9783030328573$q(electronic bk.)

Standard No.: 10.1007/978-3-030-32857-3doiSubjects--Topical Terms:

190608
Drug development.

LC Class. No.: RM301.25 / .A677 2020

Dewey Class. No.: 615.10724

Approaching complex diseasesnetwork-based pharmacology and systems approach in bio-medicine /
LDR:02407nmm a2200325 a 4500 001 571679
003 DE-He213
005 20200811093459.0
006 m d
007 cr nn 008maaau
008 200922s2020 sz s 0 eng d
020 $a 9783030328573$q(electronic bk.)
020 $a 9783030328566$q(paper)
024 7 $a 10.1007/978-3-030-32857-3 $2 doi
035 $a 978-3-030-32857-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25 $b .A677 2020
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615.10724 $2 23
090 $a RM301.25 $b .A652 2020
245 0 0 $a Approaching complex diseases $h [electronic resource] : $b network-based pharmacology and systems approach in bio-medicine / $c edited by Mariano Bizzarri.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xvi, 483 p. : $b ill., digital ; $c 24 cm.
490 1 $a Human perspectives in health sciences and technology, $x 2661-8915 ; $v v.2
520 $a This volume - for pharmacologists, systems biologists, philosophers and historians of medicine - points to investigate new avenues in pharmacology research, by providing a full assessment of the premises underlying a radical shift in the pharmacology paradigm. The pharmaceutical industry is currently facing unparalleled challenges in developing innovative drugs. While drug-developing scientists in the 1990s mostly welcomed the transformation into a target-based approach, two decades of experience shows that this model is failing to boost both drug discovery and efficiency. Selected targets were often not druggable and with poor disease linkage, leading to either high toxicity or poor efficacy. Therefore, a profound rethinking of the current paradigm is needed. Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggest that exquisitely selective compounds, compared with multitarget drugs, may exhibit lower than desired clinical efficacy. This appreciation of the role of polypharmacology has significant implications for tackling the two major sources of attrition in drug development, efficacy and toxicity. Integrating network biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets.
650 0 $a Drug development. $3 190608
650 0 $a Developmental pharmacology. $3 811076
650 1 4 $a Pharmacology/Toxicology. $3 273652
650 2 4 $a Systems Biology. $3 245824
650 2 4 $a Oncology. $3 195181
650 2 4 $a Philosophy of Medicine. $3 275170
700 1 $a Bizzarri, Mariano. $3 858422
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Human perspectives in health sciences and technology ; $v v.2. $3 858423
856 4 0 $u https://doi.org/10.1007/978-3-030-32857-3
950 $a Biomedical and Life Sciences (Springer-11642)